Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis

American Journal of Physiology - Renal Physiology

Volumn 299, Issue 6, 2010, Pages

  Hyodo, Toshitake ^a   Oda, Takashi ^a   Kikuchi, Yuichi ^a   Higashi, Keishi ^a   Kushiyama, Taketoshi ^a   Yamamoto, Kojiro ^a   Yamada, Muneharu ^a   Suzuki, Shigenobu ^a   Hokari, Ryota ^a   Kinoshita, Manabu ^a   Seki, Shuhji ^a   Fujinaka, Hidehiko ^b   Yamamoto, Tadashi ^b   Miura, Soichiro ^a   Kumagai, Hiroo ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Crescentic glomerulonephritis; Flow cytometric analysis; WKY rats

Indexed keywords

5 (4 PHENYLBUTOXY)PSORALEN; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.3; PSORALEN DERIVATIVE; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CRESCENTIC GLOMERULONEPHRITIS; DISEASE COURSE; EFFECTOR CELL; FLOW CYTOMETRY; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; MALE; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RAT; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

EID: 78649313283     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00374.2010     Document Type: Article

References (62)

1. Abdulahad WH, Kallenberg CG, Limburg PC, Stegeman CA. Urinary CD4+ effector memory T cells reflect renal disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 60: 2830-2838, 2009.
2. Abdulahad WH, Stegeman CA, Limburg PC, Kallenberg CG. CD4- positive effector memory T cells participate in disease expression in ANCA-associated vasculitis. Ann NY Acad Sci 1107: 22-31, 2007.
3. Ando T, Wu H, Watson D, Hirano T, Hirakata H, Fujishima M, Knight JF. Infiltration of canonical Vgamma4/Vdelta1 gammadelta T cells in an adriamycin-induced progressive renal failure model. J Immunol 167: 3740-3745, 2001. (Pubitemid 32910819)
4. Aranami T, Yamamura T. Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 57: 115-120, 2008.
5. Ascon M, Ascon DB, Liu M, Cheadle C, Sarkar C, Racusen L, Hassoun HT, Rabb H. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int 75: 526-535, 2009.
6. Atkins RC, Nikolic-Paterson DJ, Song Q, Lan HY. Modulators of crescentic glomerulonephritis. J Am Soc Nephrol 7: 2271-2278, 1996.
7. Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 127: 1419-1429, 2007.
8. Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 67: 1369-1381, 2005. (Pubitemid 40410438)
9. Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Beraud E. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98: 13942-13947, 2001. (Pubitemid 33116003)
10. Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, Roeck WW, Tehranzadeh J, Stanhope KL, Zimin P, Havel PJ, Griffey S, Knaus HG, Nepom GT, Gutman GA, Calabresi PA, Chandy KG. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103: 17414-17419, 2006.
11. + channel in transmembrane signaling. J Immunol 166: 1009-1015, 2001.
12. Cahalan MD, Chandy KG. Ion channels in the immune system as targets for immunosuppression. Curr Opin Biotechnol 8: 749-756, 1997. (Pubitemid 27517253)
13. Cunningham MA, Huang XR, Dowling JP, Tipping PG, Holdsworth SR. Prominence of cell-mediated immunity effectors in "pauci-immune" glomerulonephritis. J Am Soc Nephrol 10: 499-506, 1999.
14. Decher N, Kumar P, Gonzalez T, Pirard B, Sanguinetti MC. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol Pharmacol 70: 1204-1211, 2006.
15. Dolff S, Abdulahad WH, van Dijk MC, Limburg PC, Kallenberg CG, Bijl M. Urinary T cells in active lupus nephritis show an effector memory phenotype. Ann Rheum Dis. 2010 May 14. [Epub ahead of print].
16. Dong X, Bachman LA, Miller MN, Nath KA, Griffin MD. Dendritic cells facilitate accumulation of IL-17 T cells in the kidney following acute renal obstruction. Kidney Int 74: 1294-1309, 2008.
17. Friedrich M, Krammig S, Henze M, Docke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 292: 519-521, 2000. (Pubitemid 32112810)
18. - effector memory T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 291: G267-G274, 2006.
19. Fujinaka H, Yamamoto T, Feng L, Kawasaki K, Yaoita E, Hirose S, Goto S, Wilson CB, Uchiyama M, Kihara I. Crucial role of CD8- positive lymphocytes in glomerular expression of ICAM-1 and cytokines in crescentic glomerulonephritis of WKY rats. J Immunol 158: 4978-4983, 1997.
20. Fujinaka H, Yamamoto T, Takeya M, Feng L, Kawasaki K, Yaoita E, Kondo D, Wilson CB, Uchiyama M, Kihara I. Suppression of antiglomerular basement membrane nephritis by administration of anti-monocyte chemoattractant protein-1 antibody in WKY rats. J Am Soc Nephrol 8: 1174-1178, 1997.
21. Furuta T, Hotta O, Horigome I, Chiba S, Noshiro H, Miyazaki M, Satoh M, Honda S, Taguma Y. Decreased CD4 lymphocyte count as a marker predicting high mortality rate in managing ANCA related rapidly progressive glomerulonephritis. Nephron 91: 601-605, 2002.
22. + channels as targets for specific immunomodulation. Trends Pharmacol Sci 25: 280-289, 2004.
23. Grgic I, Wulff H, Eichler I, Flothmann C, Kohler R, Hoyer J. Blockade of T-lymphocyte KCa3.1 and Kv13 channels as novel immunosuppression strategy to prevent kidney allograft rejection. Transplant Proc 41: 2601-2606, 2009.
24. Gurney AM, Joshi S, Manoury B. KCNQ potassium channels: new targets for pulmonary vasodilator drugs? Adv Exp Med Biol 661: 405-417.
25. Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, Covarriubias M, Desir GV, Furuichi K, Ganetzky B, Garcia ML, Grissmer S, Jan LY, Karschin A, Kim D, Kuperschmidt S, Kurachi Y, Lazdunski M, Lesage F, Lester HA, McKinnon D, Nichols CG, O'Kelly I, Robbins J, Robertson GA, Rudy B, Sanguinetti M, Seino S, Stuehmer W, Tamkun MM, Vandenberg CA, Wei A, Wulff H, Wymore RS. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacol Rev 55: 583-586, 2003.
26. Haas C, Ryffel B, Le Hir M. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J Immunol 158: 5484-5491, 1997.
27. Haas C, Ryffel B, Le Hir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB X NZW)F1 mice. J Immunol 160: 3713-3718, 1998.
28. + channel Kv1.3 by the ubiquitin ligase Nedd4-2 and the serum and glucocorticoid inducible kinase SGK1. J Cell Physiol 199: 194-199, 2004.
29. Holdsworth SR, Neale TJ, Wilson CB. Abrogation of macrophage-dependent injury in experimental glomerulonephritis in the rabbit. Use of an antimacrophage serum. J Clin Invest 68: 686-698, 1981.
30. Huang XR, Tipping PG, Apostolopoulos J, Oettinger C, D'Souza M, Milton G, Holdsworth SR. Mechanisms of T cell-induced glomerular injury in anti-glomerular basement membrane (GBM) glomerulonephritis in rats. Clin Exp Immunol 109: 134-142, 1997.
31. Ikezumi Y, Atkins RC, Nikolic-Paterson DJ. Interferon-gamma augments acute macrophage-mediated renal injury via a glucocorticoid-sensitive mechanism. J Am Soc Nephrol 14: 888-898, 2003.
32. Karkar AM, Tam FW, Steinkasserer A, Kurrle R, Langner K, Scallon BJ, Meager A, Rees AJ. Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor, and soluble TNF receptor. Kidney Int 48: 1738-1746, 1995.
33. Kitching AR, Holdsworth SR, Tipping PG. IFN-gamma mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis. J Am Soc Nephrol 10: 752-759, 1999.
34. 2+- dependent mechanism. Am J Physiol Cell Physiol 290: C345-C351, 2006.
35. Liu H, Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 180: 7948-7957, 2008.
36. Matheu MP, Beeton C, Garcia A, Chi V, Rangaraju S, Safrina O, Monaghan K, Uemura MI, Li D, Pal S, de la Maza LM, Monuki E, Flugel A, Pennington MW, Parker I, Chandy KG, Cahalan MD. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block. Immunity 29: 602-614, 2008.
37. Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R, Motoki K, Kamishohara M, Seki S. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice. J Immunol 166: 6578-6584, 2001.
38. Nikolic-Paterson DJ, Atkins RC. The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 16, Suppl 5: 3-7, 2001.
39. Paust HJ, Turner JE, Steinmetz OM, Peters A, Heymann F, Holscher C, Wolf G, Kurts C, Mittrucker HW, Stahl RA, Panzer U. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol 20: 969-979, 2009.
40. Pereira LE, Villinger F, Wulff H, Sankaranarayanan A, Raman G, Ansari AA. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques. Exp Biol Med (Maywood) 232: 1338-1354, 2007.
41. Pipkin ME, Rao A. SnapShot: effector and memory T cell differentiation. Cell 138: 606 e601-602, 2009.
42. Ring GH, Dai Z, Saleem S, Baddoura FK, Lakkis FG. Increased susceptibility to immunologically mediated glomerulonephritis in IFN-gamma- deficient mice. J Immunol 163: 2243-2248, 1999.
43. Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, Wulff H, Beeton C, Judge SI, Kerr DA, Knaus HG, Chandy KG, Calabresi PA. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci USA 102: 11094-11099, 2005.
44. Sakatsume M, Gejyo F. Effector T cells and macrophages in urine as a hallmark of systemic vasculitis accompanied by crescentic glomerulonephritis. Nephrol Dial Transplant 18: 607-609, 2003.
45. Sakatsume M, Xie Y, Ueno M, Obayashi H, Goto S, Narita I, Homma N, Tasaki K, Suzuki Y, Gejyo F. Human glomerulonephritis accompanied by active cellular infiltrates shows effector T cells in urine. J Am Soc Nephrol 12: 2636-2644, 2001.
46. Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol 96: 41-101, 2007.
47. Schreiner GF, Cotran RS, Pardo V, Unanue ER. A mononuclear cell component in experimental immunological glomerulonephritis. J Exp Med 147: 369-384, 1978.
48. Seder RA, Ahmed R. Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol 4: 835-842, 2003. (Pubitemid 37098653)
49. Shahrara S, Huang Q, Mandelin AM, 2nd, Pope RM. TH-17 cells in rheumatoid arthritis. Arthriris Res Ther 10: R93, 2008.
50. Tang WW, Feng L, Vannice JL, Wilson CB. Interleukin-1 receptor antagonist ameliorates experimental anti-glomerular basement membrane antibody-associated glomerulonephritis. J Clin Invest 93: 273-279, 1994.
51. Tipping PG, Holdsworth SR. T cells in crescentic glomerulonephritis. J Am Soc Nephrol 17: 1253-1263, 2006.
52. Tomosugi NI, Cashman SJ, Hay H, Pusey CD, Evans DJ, Shaw A, Rees AJ. Modulation of antibody-mediated glomerular injury in vivo by bacterial lipopolysaccharide, tumor necrosis factor, and IL-1. J Immunol 142: 3083-3090, 1989.
53. Totsuka T, Kanai T, Iiyama R, Uraushihara K, Yamazaki M, Okamoto R, Hibi T, Tezuka K, Azuma M, Akiba H, Yagita H, Okumura K, Watanabe M. Ameliorating effect of anti-inducible costimulator monoclonal antibody in a murine model of chronic colitis. Gastroenterology 124: 410-421, 2003. (Pubitemid 36169258)
54. Varela-Calvino R, Ellis R, Sgarbi G, Dayan CM, Peakman M. Characterization of the T-cell response to coxsackievirus B4: evidence that effector memory cells predominate in patients with type 1 diabetes. Diabetes 51: 1745-1753, 2002.
55. Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hansel W, Chandy KG. Kv1-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol 65: 1364-1374, 2004.
56. + channel responses during proliferation and activation in macrophages. J Biol Chem 278: 46307-46320, 2003.
57. + channel in macrophages. J Biol Chem 281: 37675-37685, 2006.
58. Villalonga N, Escalada A, Vicente R, Sanchez-Tillo E, Celada A, Solsona C, Felipe Kv1 A.3/Kv1.5. heteromeric channels compromise pharmacological responses in macrophages. Biochem Biophys Res Commun 352: 913-918, 2007.
59. Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. J Clin Invest 111: 1703-1713, 2003.
60. Wuttke TV, Lerche H. Novel anticonvulsant drugs targeting voltage-dependent ion channels. Expert Opin Investig Drugs 15: 1167-1177, 2006.
61. Yao X, Chang AY, Boulpaep EL, Segal AS, Desir GV. Molecular cloning of a glibenclamide-sensitive, voltage-gated potassium channel expressed in rabbit kidney. J Clin Invest 97: 2525-2533, 1996.
62. Yoshida M, Nakata M, Yamato S, Dezaki K, Sugawara H, Ishikawa SE, Kawakami M, Yada T, Kakei M. Voltage-dependent metabolic regulation of Kv2.1 channels in pancreatic beta-cells. Biochem Biophys Res Commun 396: 304-309, 2010.